OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

Summary by AI BETAClose X

OKYO Pharma Limited has expanded its Scientific Advisory Board with the appointment of international expert Marta Sacchetti, MD, PhD, who brings significant experience in ocular inflammatory and degenerative diseases, particularly neuropathic corneal pain (NCP). This strategic addition aims to enhance OKYO's global clinical development strategy for its investigational therapy, Urcosimod, which has received Fast Track designation from the FDA for NCP. The company recently announced positive Phase 2 data for Urcosimod in NCP patients and plans to initiate a 150-patient Phase 2b/3 study in the first half of the year.

Disclaimer*

UK 100

Latest directors dealings